BioCryst Pharmaceuticals BCRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total liabilities & equity?
- BioCryst Pharmaceuticals (BCRX) reported total liabilities & equity of $465.05M in Q1 2026.
- How has BioCryst Pharmaceuticals's total liabilities & equity changed year-over-year?
- BioCryst Pharmaceuticals's total liabilities & equity decreased by 3.1% year-over-year, from $480.05M to $465.05M.
- What is the long-term trend for BioCryst Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total liabilities & equity has grown at a 9.0% compound annual growth rate (CAGR), from $334.72M to $514.16M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.